Key facts
- PRICE T ROWE ASSOCIATES INC /MD/ filed SCHEDULE 13G/A for AKERO THERAPEUTICS INC COMMON STOCK (AKRO).
- Disclosed ownership: 4.8%.
- Date of event: 30 Sep 2025.
PRICE T ROWE ASSOCIATES INC /MD/ - 30 Sep 2025 SCHEDULE 13G/A Report for AKERO THERAPEUTICS INC COMMON STOCK (AKRO)
- Filing Manager
- PRICE T ROWE ASSOCIATES INC /MD/
- Reporting Manager
- T. Rowe Price Associates, Inc.
- Security
- AKERO THERAPEUTICS INC COMMON STOCK
- Symbol
- AKRO
- Shares outstanding
- 79,376,583 shares
- Disclosed Ownership
- 3,810,076 shares
- Ownership
- 4.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 12:19:23 UTC
- Date of event
- 30 Sep 2025
- SEC
- View on sec.gov
Key filing fact
PRICE T ROWE ASSOCIATES INC /MD/ disclosed 4.8% ownership in AKERO THERAPEUTICS INC COMMON STOCK (AKRO) on 30 Sep 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Nov 2025, 12:19.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (1)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 4.8% | 3,810,076 | 3,731,603 | 0 | Ellen York | Vice President |
CIK / CUSIP context first